EP4713461A2 - Durch proinflammatorisches cytokin verstärkte rekombinante steap1-rezeptoren - Google Patents

Durch proinflammatorisches cytokin verstärkte rekombinante steap1-rezeptoren

Info

Publication number
EP4713461A2
EP4713461A2 EP24808125.9A EP24808125A EP4713461A2 EP 4713461 A2 EP4713461 A2 EP 4713461A2 EP 24808125 A EP24808125 A EP 24808125A EP 4713461 A2 EP4713461 A2 EP 4713461A2
Authority
EP
European Patent Office
Prior art keywords
seq
sequence
set forth
cells
steap1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24808125.9A
Other languages
English (en)
French (fr)
Inventor
John K. Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of EP4713461A2 publication Critical patent/EP4713461A2/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP24808125.9A 2023-05-16 2024-05-16 Durch proinflammatorisches cytokin verstärkte rekombinante steap1-rezeptoren Pending EP4713461A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363502596P 2023-05-16 2023-05-16
PCT/US2024/029755 WO2024238832A2 (en) 2023-05-16 2024-05-16 Pro-inflammatory cytokine enhanced steap1 recombinant receptors

Publications (1)

Publication Number Publication Date
EP4713461A2 true EP4713461A2 (de) 2026-03-25

Family

ID=93520227

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24808125.9A Pending EP4713461A2 (de) 2023-05-16 2024-05-16 Durch proinflammatorisches cytokin verstärkte rekombinante steap1-rezeptoren

Country Status (4)

Country Link
EP (1) EP4713461A2 (de)
JP (1) JP2026517179A (de)
AU (1) AU2024274301A1 (de)
WO (1) WO2024238832A2 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3955352B2 (ja) * 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
WO2019246593A2 (en) * 2018-06-22 2019-12-26 Fred Hutchinson Cancer Research Center Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders
MX2021000617A (es) * 2018-07-18 2021-04-13 Amgen Inc Receptores quimericos de steap1 y metodos de uso de los mismos.
TW202300644A (zh) * 2021-02-24 2023-01-01 中國大陸商杭州啟函生物科技有限公司 免疫細胞中的嵌合抗原受體
EP4476267A4 (de) * 2022-02-11 2026-01-07 Fred Hutchinson Cancer Center Chimäre antigenrezeptoren zur bindung von steap1

Also Published As

Publication number Publication date
JP2026517179A (ja) 2026-05-28
AU2024274301A9 (en) 2025-12-18
WO2024238832A3 (en) 2025-01-02
WO2024238832A2 (en) 2024-11-21
AU2024274301A1 (en) 2025-12-11

Similar Documents

Publication Publication Date Title
JP2023036712A (ja) 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
JP2019536437A (ja) Ｈｐｖ特異的結合分子
WO2019246593A2 (en) Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders
US20250144139A1 (en) Chimeric antigen receptors binding steap1
CA3199205A1 (en) Anti-bcma chimeric antigen receptors
US12351618B2 (en) Engineered trimeric CD70 proteins and uses thereof
JP7859985B2 (ja) Ｃｄ３３を標的にするキメラ抗原受容体
EP4126248A2 (de) Humane anti-cd33-antikörper und verwendungen davon
CN115835873A (zh) 用于产生表达重组受体的供体分批细胞的方法
CN115361968A (zh) 在抗原靶向免疫疗法中增加抗原阴性细胞死亡
US12570758B2 (en) Chimeric antigen receptors targeting CD33
WO2024238832A2 (en) Pro-inflammatory cytokine enhanced steap1 recombinant receptors
US20250319130A1 (en) Recombinant receptors binding b cell activation factor receptor and uses thereof
US20260091114A1 (en) Chimeric antigen receptors binding nectin-4
US20240091260A1 (en) Chimeric antigen receptors that bind preferentially expressed antigen in melanoma (prame)/hla-a2 to treat cancer
WO2025207642A1 (en) Cxcr3 isoforms to improve recombinant receptor trafficking
EP4724076A2 (de) Systeme und verfahren zur in-vivo-ausrichtung von zelltherapien auf ein organ
JP2026503849A (ja) 免疫細胞の機能を増強するための誘導型サイトカイン導入遺伝子
WO2025097015A1 (en) Clec2a-binding therapeutics
JP2024542027A (ja) 細胞標的療法を利用したがんの治療及び関連する研究プロトコル

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251208

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: UPC_APP_0014174_4713461/2026

Effective date: 20260429